Skip to main content
. 2021 Mar 15;11:5934. doi: 10.1038/s41598-021-85202-9

Figure 1.

Figure 1

Neutralizing antibody titers and anti-SARS-CoV-2 IgG, IgM responses of COVID-19 patients. (A) The neutralizing antibody titers of serum antibodies against SARS-CoV-2 at an evaluation point of the 75% inhibitory dose (ID75). (B,C) The serum titer against recombinant SARS-CoV-2 spike S1 + S2 protein. (B) Total IgG, (C) IgM, expressed as the OD at 450 nm and the half-maximal binding (OD 50%). (D,E) The serum titer against recombinant SARS-CoV-2 spike RBD protein. (D) Total IgG, (E) IgM, expressed as the OD at 450 nm and the OD 50%. OU, serum samples collected from patients in the ICU of Osaka University Hospital (n = 12); Ju, serum samples collected from patients in Osaka City Juso Hospital (n = 31). All the data are expressed as the mean ± SEM. Statistical evaluation was performed by Mann–Whitney U test (A, common logarithmic transformation); *p < 0.05; **p < 0.01. Graphs made in GraphPad Prism version 8.4.3, https://www.graphpad.com/scientific-software/prism/.

HHS Vulnerability Disclosure